INFO & CONTACTS:  +39 02 2390 1

Monocentric, open-label, single-arm, phase I/II clinical trial to evaluate the use of the ONCOGREEN galenic formulation consisting of indocyanine green (ICG) with autologous extracellular vesicles (EVs) for in vivo diagnostics of solid neoplasms undergoing surgical removal

Phase: Phase I-II clinical trials

Principal Investigator: Prof. Mazzaferro Vincenzo

Main Facility: Chirurgia Generale Oncologica 1 – Epato-Gastro-Pancreatica e Trapianto di Fegato

Drug: ONCOGREEN galenic formulation

Pathologies: Mesenchymal tumors in adults (sarcoma, GIST, others)

ClinicalTrials.gov: Read more about clinical trials

The ONCOGREEN study is a monocentric, open-label, single-arm phase I/II clinical trial designed to evaluate the safety and diagnostic performance of a galenic formulation called OncoGreen, consisting of indocyanine green (ICG) combined with autologous extracellular vesicles (EVs). 

Extracellular vesicles are isolated from the patient’s plasma through plasmapheresis, loaded with ICG, and then reinfused intravenously. During surgery, fluorescence imaging allows the dye to highlight tumor tissue and margins, potentially improving intraoperative visualization and tumor removal. 

Phase I aims to assess safety, tolerability and determine the optimal dose, while Phase II evaluates the effectiveness of the technique in improving intraoperative tumor visualization

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe